GeminiBio’s customers engineer T cells to target a specific cancer, and using AI will make the T cells stronger and more effective.
New benchmark shows top LLMs achieve only 29% pass rate on OpenTelemetry instrumentation, exposing the gap between ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results